Esperion Therapeutics, Inc. cash flow to debt ratio of -2.39% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Esperion Therapeutics, Inc.'s free cash flow has increased -45.38% from $-23.97M last year to $-13.09M, signaling increasing performance

Esperion Therapeutics, Inc.'s debt to equity ratio is -1.77, signaling that the company spent its equity and risk bankruptcy.

Esperion Therapeutics, Inc.'s debt to equity ratio is -1.77, signaling that the company spent its equity and risk bankruptcy.

Esperion Therapeutics, Inc. has a net debt to EBITDA ratio of 5.95x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Esperion Therapeutics, Inc.'s interest coverage ratio is 1.67, which means that the company struggles to meet interest obligations, signaling financial risk.

Esperion Therapeutics, Inc.'s profit margin has increased (-88.60%) in the last year from -15.57% to -1.77%, signaling increasing performance

Esperion Therapeutics, Inc.'s short-term assets of $462.57M exceed its short-term liabilities of $300.81M

Esperion Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Esperion Therapeutics, Inc.'s return on equity of 1.99%, is lower than 15.00%, indicating bad performance

Esperion Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Esperion Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Esperion Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Esperion Therapeutics, Inc. has negative free cash flow, indicating cash burn

Esperion Therapeutics, Inc.'s yearly earnings has increased -56.17% since last year from $-51.74M to $-22.68M, signaling increasing performance

Esperion Therapeutics, Inc.'s yearly revenue has increased 21.31% since last year from $332.31M to $403.13M, signaling increasing performance

ROIC 30.98% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Esperion Therapeutics, Inc.'s 3-year revenue CAGR of 74.80% is positive, indicating growing revenue over the past 3 years

Esperion Therapeutics, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Esperion Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Esperion Therapeutics, Inc. has insufficient data to evaluate this check.

Esperion Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Esperion Therapeutics, Inc. is overvalued relative to its fair value price of 0.21 based on EBITDA multiple model

Esperion Therapeutics, Inc. has an EV/EBITDA ratio of 16.30x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Esperion Therapeutics, Inc. is overvalued relative to its fair value price of -50.20 based on Earnings Fair Value model

Esperion Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Esperion Therapeutics, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Esperion Therapeutics, Inc. has a price-to-sales ratio of 1.91x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue